John Newman
Stock Analyst at Canaccord Genuity
(2.19)
# 2,905
Out of 5,058 analysts
86
Total ratings
45.33%
Success rate
-5.18%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Initiates: Buy | $126 | $107.13 | +17.61% | 1 | Nov 12, 2025 | |
| ACLX Arcellx | Maintains: Buy | $121 → $130 | $89.62 | +45.06% | 9 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $702.75 | +20.95% | 19 | Oct 23, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $8.51 | +146.77% | 2 | Oct 21, 2025 | |
| MRUS Merus | Downgrades: Hold | $67 → $97 | $96.04 | +1.00% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $28.63 | -23.16% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.26 | +1,011.11% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $101.43 | +69.02% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $13.74 | +23.73% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.09 | +633.94% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $4.42 | +465.61% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.58 | +1,286.00% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.15 | +501.40% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.04 | +380.77% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $22.34 | +96.96% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.53 | +161.53% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.86 | +455.56% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.20 | - | 1 | Sep 13, 2017 |
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $107.13
Upside: +17.61%
Arcellx
Nov 3, 2025
Maintains: Buy
Price Target: $121 → $130
Current: $89.62
Upside: +45.06%
Regeneron Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $850
Current: $702.75
Upside: +20.95%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $8.51
Upside: +146.77%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $96.04
Upside: +1.00%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $28.63
Upside: -23.16%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.26
Upside: +1,011.11%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $101.43
Upside: +69.02%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $13.74
Upside: +23.73%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.09
Upside: +633.94%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.42
Upside: +465.61%
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.58
Upside: +1,286.00%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.15
Upside: +501.40%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.04
Upside: +380.77%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $22.34
Upside: +96.96%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.53
Upside: +161.53%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.86
Upside: +455.56%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.20
Upside: -